Two estimates consensus is for FY23 EPS $4.26. Raises FY23 adjusted non-GAAP EBITDA view to $78.0M-$84.0M, up from the previously disclosed estimated range of $74.0M-$80.0M. Reaffirms FY23 Adjusted non-GAAP research and development and Adjusted non-GAAP SG&A $41.0M-$45.0M, and $86.0M-$90.0M, respectively. “Due to the strength and momentum of our business, we are raising our full year Adjusted non-GAAP EPS and Adjusted non-GAAP EBITDA guidance. Our previously disclosed Adjusted non-GAAP research and development and Adjusted non-GAAP SG&A expense ranges remain the same as we continue to invest in our robust pipeline of products. We look forward to sharing additional details during our second quarter earnings call on August 8th,” stated Scott Tarriff, President and CEO of Eagle Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EGRX:
- Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023
- Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance
- Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)
- Eagle Pharmaceuticals: First patient enrolled in Phase 2 study of CAL02
- Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance